Why Is Palforzia So Hard to Find? [Explained for 2026]

If you or your child has been trying to fill a Palforzia prescription in 2026, you may have already encountered empty shelves, confused pharmacists, or flat-out rejections. You are not imagining it — Palforzia is genuinely hard to find right now, and the situation is only going to get more difficult as the year progresses. Here is everything you need to know about why that is happening and what your options are.

What Is Palforzia, and Why Does It Matter?

Palforzia (peanut allergen powder-dnfp) was the first and only FDA-approved oral immunotherapy (OIT) for peanut allergy. Approved in January 2020 for children ages 4 through 17, and later expanded to toddlers ages 1 through 3 in 2024, it represented a landmark moment in food allergy treatment. For decades, the only management option for peanut allergy was strict avoidance and carrying an epinephrine auto-injector. Palforzia changed that by offering a way to desensitize children's immune systems over time.

The treatment works in three phases: Initial Dose Escalation (done in a single day at a clinic), Up-Dosing (12 levels spread over roughly six months), and Maintenance (300 mg of peanut protein daily for the long term). The 3 mg dose is reached during the Up-Dosing phase and is a critical checkpoint in building tolerance.

The Big Reason Palforzia Is So Hard to Find in 2026: Discontinuation

Stallergenes Greer, the manufacturer of Palforzia, announced in January 2026 that it would voluntarily discontinue commercialization of the drug effective July 31, 2026. The company was clear that this decision has nothing to do with the safety, quality, or effectiveness of the drug. Palforzia works. It just wasn't profitable enough to continue.

The reasons behind this commercial failure are complex:

The REMS (Risk Evaluation and Mitigation Strategy) program required by the FDA created heavy administrative burdens for prescribing allergists, limiting how many clinics could offer the treatment.

Every first dose at a new dosing level had to be administered in a certified clinical setting — creating significant time and travel demands for families.

The COVID-19 pandemic disrupted the critical early years of commercialization after the 2020 approval.

Many allergists offering peanut OIT were already using non-pharmaceutical peanut flour at a fraction of the cost, providing competition from within the specialty itself.

Insurance coverage required prior authorization and was inconsistent across plans, making access difficult for many families.

The Timeline: What Happens When?

Understanding the discontinuation timeline helps explain why Palforzia is increasingly hard to find:

January 2026: Stallergenes Greer publicly announced the voluntary discontinuation decision.

March/April 2026: Healthcare providers advised not to start new patients on Palforzia. Initial Dose Escalation packs became unavailable first.

July 31, 2026: Full commercialization ends. Supply for patients already on therapy will be limited to remaining inventory.

This means that even patients currently on Palforzia therapy are in a race against the clock to figure out their next steps before supply runs out.

Why Can't I Find It at My Pharmacy?

Palforzia was never a drug you'd find stocked at your typical retail pharmacy in the same way you'd find a common antibiotic. Because of the REMS program requirements, it had to be dispensed through specialty pharmacies and healthcare settings certified to handle it. As the discontinuation date approaches, remaining inventory is becoming concentrated and harder to locate, especially for specific dose levels like the 3 mg up-dosing capsules.

Patients report calling pharmacy after pharmacy — specialty pharmacies, hospital pharmacies, and mail-order services — only to be told the medication is out of stock or no longer being ordered. This is the reality of a drug in wind-down mode.

38,440+ patients found their medications in stock

38K+

Find Palforzia 3 mg In Stock Today →

Is There Any Supply Left at All?

Yes — but it is dwindling. Stallergenes Greer committed to supporting patients already on therapy through an orderly transition. The Palforzia Pathway Patient Hub (1-844-PALFORZ) remains active and can help connect current patients with remaining supply and transition support. However, that supply is finite and will not be replenished after July 31, 2026.

How medfinder Can Help You Find Palforzia

When every pharmacy call comes up empty, medfinder can help. medfinder calls pharmacies near you — specialty pharmacies, hospital outpatient pharmacies, and other certified dispensers — to check which ones have Palforzia at your specific dose level in stock and can fill your prescription. Rather than spending hours on hold, you get a text with the results. Given how time-sensitive the Palforzia supply situation is, this kind of targeted search matters.

Skip the calls, skip the stress.

Find Palforzia 3 mg In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

What If You Can't Find Palforzia at All?

If Palforzia truly can't be found, do not abruptly stop treatment without talking to your child's allergist. Abrupt discontinuation can reverse desensitization progress. Your allergist may be able to transition your child to an office-based OIT protocol using peanut flour, or discuss other options like omalizumab (Xolair). Read our guide on alternatives to Palforzia for a full breakdown of what patients are doing next.

What Comes Next for Peanut Allergy Treatment?

The field is not standing still. Omalizumab (Xolair) was FDA-approved for food allergy in February 2024 and can reduce the severity of reactions to peanuts and other allergens in children ages 1 and older. Office-based peanut OIT programs are expanding at academic centers and private allergy practices. Investigational approaches including epicutaneous immunotherapy (skin patches) and sublingual immunotherapy are in clinical trials. The loss of Palforzia is a setback, but the peanut allergy treatment landscape continues to evolve.

Key Takeaways

Palforzia is hard to find because Stallergenes Greer is voluntarily discontinuing it as of July 31, 2026 — for commercial, not safety, reasons.

Remaining supply is limited and concentrated at specialty and hospital pharmacies.

If you're currently on Palforzia, talk to your allergist immediately about your transition plan.

medfinder can help you search pharmacies efficiently while supply still exists.

Do not stop Palforzia abruptly — always consult your allergist before making any changes.